Tuesday, March 21, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

NIAID Backs Kineta Broad-Spectrum Antiviral Therapies

by Global Biodefense Staff
July 31, 2015
Development of Broad Spectrum Antivirals

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract to Kineta, Inc. for the development of broad-spectrum antiviral therapeutics to address a variety of viral diseases.

Kineta’s novel class of molecules has been shown in pre-clinical tests to inhibit a diverse range of viral pathogens including Ebola, influenza A & B, dengue, West Nile, Lassa fever, respiratory syncytial virus and human coronaviruses.

The funding is valued at $1.4M for the base award, with options to exercise an additional $2.52 M over two to three years.

“Kineta’s small molecule compounds trigger a natural immune response by targeting processes that activate the innate human immune transcription factor, IRF-3, a critical responder that drives antiviral gene expression to suppress viral replication,” said Kristin Bedard, Director and Head of Kineta’s Virology Program.

Kineta’s innate immune antiviral compounds offer novel mechanisms of action that activate the innate immune transcription factor IRF-3, a critical first responder that is essential for inhibiting viral replication and clearing infection. Unlike direct acting antivirals, these host-directed compounds have demonstrated efficacy across a broad spectrum of RNA and DNA viruses and offer the potential for a pan-viral therapy that circumvents drug resistance.

Tags: AntiviralsAwards

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC